Dynavax hepatitis C drug brings antiviral response in early-stage trial

01/26/2010 | Reuters

An early-stage study showed that high doses of Dynavax Technologies' hepatitis C drug reduced the severity of viral infection in patients who also received other antivirals. The treatment, SD-101, outperformed older drugs in stimulating the production of two forms of interferons, which help the immune system fight viruses and other pathogens.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY